News & Updates

Show Multimedia Only

Energy-reduced MedDiet plus physical activity prevents T2D in persons with obesity

24 Sep 2025

An intensive intervention with energy-reduced Mediterranean diet (MedDiet) combined with physical activity demonstrates greater efficacy than an ad libitum MedDiet only in lowering the incidence of diabetes in persons with overweight or obesity and metabolic syndrome, according to a study.

Energy-reduced MedDiet plus physical activity prevents T2D in persons with obesity

24 Sep 2025

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

24 Sep 2025

Metabolic dysfunction–associated steatotic liver disease (MASLD) can lead to the development of metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma (HCC). Hong Kong studies show that sodium-glucose cotransporter 2 inhibitors (SGLT2i), such as empagliflozin, can reduce liver fat in nondiabetic patients with MASLD and lower the risk of HCC in patients with coexisting type 2 diabetes (T2D) and chronic hepatitis B (CHB).

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

24 Sep 2025

Pomegranate supplementation mitigates several cardiometabolic risk factors

24 Sep 2025

Pomegranate supplementation helps improve certain risk factors for cardiometabolic syndrome, including body weight, BMI, blood pressure, fasting blood glucose, total cholesterol, and high-density lipoprotein (HDL), according to a systematic review and meta-analysis.

Pomegranate supplementation mitigates several cardiometabolic risk factors

24 Sep 2025

Original New Drug Application Approvals by US FDA (16-31 August 2025)

24 Sep 2025

New drug applications approved by US FDA as of 16-31 August 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 August 2025)

24 Sep 2025

Mediterranean–DASH diet improves health outcomes in T2D, hypertension

22 Sep 2025

Adherence to the Mediterranean–Dietary Approaches to Stop Hypertension (DASH) diet leads to improvements in anthropometric, laboratory parameters, and blood pressure (BP) in patients with type 2 diabetes (T2D) and hypertension, reports a study. This intervention also improves satiety levels throughout the day.

Mediterranean–DASH diet improves health outcomes in T2D, hypertension

22 Sep 2025

Semaglutide works well for Asians with obesity

22 Sep 2025

Once-weekly treatment with semaglutide is safe and induces weight loss in Asians with obesity, according to the phase III STEP 11 trial.

Semaglutide works well for Asians with obesity

22 Sep 2025

GLP-1 RAs work well for managing T2D, obesity in children

21 Sep 2025 by

Children and teens with type 2 diabetes (T2D) or obesity benefit from glucagon-like peptide-1 receptor agonists (GLP-1RAs), which help improve blood sugar and weight, according to a meta-analysis.

GLP-1 RAs work well for managing T2D, obesity in children

21 Sep 2025

Statins may protect adults with T1DM against all-cause death, CVD

19 Sep 2025

The use of statins for primary prevention in adults with type 1 diabetes mellitus (T1DM) appears to prevent all-cause mortality and major cardiovascular disease (CVD), with an acceptable safety profile, a study has shown.

Statins may protect adults with T1DM against all-cause death, CVD

19 Sep 2025

Clinical research in non-university public hospitals correlated with improved patient outcomes

19 Sep 2025 by

More than 10 percent of full-time clinicians in Hong Kong’s non-university public hospitals engaged in original research as principal investigators (PIs), contributing to nearly one-third of the city’s peer-reviewed studies published in 2016–2021. Their clinical research activity is correlated with improved patient outcomes.

Clinical research in non-university public hospitals correlated with improved patient outcomes

19 Sep 2025

Optimal glycaemic control associated with lower pancreatic cancer risk in T2D

19 Sep 2025 by

In patients with type 2 diabetes (T2D), optimal glycaemic control is associated with lower risks of pancreatic cancer as well as pancreatic cancer–related mortality and all-cause mortality, a territory-wide population-based retrospective cohort study has shown.

Optimal glycaemic control associated with lower pancreatic cancer risk in T2D

19 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Energy-reduced MedDiet plus physical activity prevents T2D in persons with obesity

Energy-reduced MedDiet plus physical activity prevents T2D in persons with obesity

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

Pomegranate supplementation mitigates several cardiometabolic risk factors

Pomegranate supplementation mitigates several cardiometabolic risk factors

Original New Drug Application Approvals by US FDA (16-31 August 2025)

Original New Drug Application Approvals by US FDA (16-31 August 2025)

Mediterranean–DASH diet improves health outcomes in T2D, hypertension

Mediterranean–DASH diet improves health outcomes in T2D, hypertension

Semaglutide works well for Asians with obesity

Semaglutide works well for Asians with obesity

GLP-1 RAs work well for managing T2D, obesity in children

GLP-1 RAs work well for managing T2D, obesity in children

Statins may protect adults with T1DM against all-cause death, CVD

Statins may protect adults with T1DM against all-cause death, CVD

Clinical research in non-university public hospitals correlated with improved patient outcomes

Clinical research in non-university public hospitals correlated with improved patient outcomes

Optimal glycaemic control associated with lower pancreatic cancer risk in T2D

Optimal glycaemic control associated with lower pancreatic cancer risk in T2D